What are the implications for the development of oncology in China in the 2020 clinical oncology school year?

(Health Times reporter Xu Wei, intern reporter Tan Qixin Qiu Yue Zhao Yuanji)
" As the first live-streamed oncology event in 2020, i think it's a multidisciplinary alliance and a mutual promotion of top academic fields in the transmission of the important implications of the global tumor progress of 2020 in China." 2020 POST-ASCO President, Chinese Medical Association Oncology Association-designate, Sichuan Cancer Hospital President Lin Wei to the Health Times reporter.
sponsored by the Chinese Medical Association, the Chinese Medical Association Cancer Credit Association, the Southern Clinical Oncology Research Association, the Guangdong Medical Association Oncology Credit Association, Sichuan Cancer Society co-sponsored by the Clinical Oncology Conference (2020 POST-ASCO Conference) July 10-11, 2020, July 18-19.President Linton uses his spare time to diagnose patients who come from the famous. Xu Yuzhao
difficult to treat difficult tumors, multidisciplinary joint diagnosis is the key
" lymphoma and sarcoma diagnosis is the most difficult, because subtypes are particularly many, in the pathological diagnosis is very difficult, " the Chinese Medical Association Of China Cancer Credit Association-designate, Sichuan Cancer Hospital President Lin Wei in an exclusive interview with reporters revealed, "to lymphoma, pathologists once encountered lymphoma will feel a special headache." Because there are 67 subtypes of lymphoma, it is extremely difficult to accurately diagnose."
President Lin Yu pointed out that to achieve accurate diagnosis and treatment, it is necessary to ensure the combination of higher-level hospitals and primary hospitals, as well as multidisciplinary integration.
"to a patient is not as good as teaching a doctor, China's overall level of cancer diagnosis and treatment to really improve the level of grass-roots doctors to improve the level of cancer diagnosis and treatment, only the short board up, the overall will have a big improvement. President Lin yu suggested that tumor patients, especially those with lymphoma, which are difficult to diagnose, should contact the primary hospital with the higher hospital for consultation. Doctors in primary hospitals consult with experts in higher-level hospitals on the diagnosis and treatment of tumors, so as to cultivate the level of clinical diagnosis of primary oncologists, while practitioners in the oncology departments of primary hospitals should receive specialized training and obtain a professional practice certificate before they can take up their posts.
in multidisciplinary union, the larger the root of the tree, the higher it can grow higher. "Clinical surgeons should pay more attention to the progress of other disciplines, combine knowledge and supplement, and the treatment of a single tumor can draw on the treatment experience of other tumors." Horizontal knowledge can help surgical clinicians break the bottleneck in this discipline," Dean Lin said, for example, clinical practice has shown that immunotherapy PD-1/PD-L1 combination can be used in clinical treatment of melanoma in addition to being used in the clinical treatment of melanoma. In addition, pD-L1 for lymphcancer treatment has been clinically proven to be also suitable for bladder cancer patients and lung cancer patients, both of whom have significantly improved their survival after use.in addition,
, in order to prevent the occurrence and development of cancer, Lin suggested that patients themselves should pay attention to nutrition, rest, mood of the "six-word policy", from changing their own bad habits, for example, through exercise and a variety of ways to adjust their mood.
domestic innovation drugs are no worse than foreign
" at present many cancer innovation drugs, objectively speaking, no worse than foreign countries. Diagnosis and treatment have become more and more international." Li Jianyong, honorary chairman of the hematology committee of the China Anticancer Association and director of the hematology department of Jiangsu Provincial People's Hospital, told reporters.Li Jianyong,
, pointed out that, first, thanks to the policy of priority approval and review of the Drug Review Center of the State Drug Administration, the process of launching innovative drugs has been accelerated, and second, innovative pharmaceutical companies are paying more and more attention to increasing the cost of drug research and development.
for example, clinical trials of Zebutini, led by Li Jianyong, in the treatment of chronic lymphocytic leukemia showed no difference in efficacy, good efficacy and fewer side effects.
and new oral drugs, compared to intravenous input many patients can not go to the hospital will delay treatment, do not need to go to the hospital can achieve good results, outbreaks and other sudden public health events on patients will be relatively small impact. Li Jianyong for example, "We have a lot of slow-down patients, drugs alone can be very well controlled, during the outbreak, we to reduce the number of patients to the hospital, can be family, mail to provide patients with drugs."
in addition, Li Jianyong suggested that the outbreak may be a long-term and sustained impact, and the burden of blood patients is relatively heavy, treatment as far as possible not to the hospital, at the same time to maintain contact with the doctor, as far as possible to ensure standardized treatment. Online and offline combination of academic seminars and consultations will become a trend. For some, especially in the grass-roots areas, the first time can accept the most advanced cutting-edge medicine, is the medical continuing education and online diagnosis and treatment of the new model.
Yu Shiying: Rare tumors should be included in the list of rare diseases
"At present, the country attaches full importance to rare diseases, the introduction of a list of rare diseases. However, at present rare tumors have not been included in the list of rare diseases," said Yu Shiying, deputy chairman of the Committee of Experts on Rare Oncology of the Chinese Society of Clinical Oncology and affiliated with Tongji Medical College of Huazhong University of Science and Technology, in an exclusive interview with the Health Times.
rare tumors are malignant tumors with a incidence rate of less than six in 100,000, and if the incidence is less than two in 100,000, it is a super-rare tumor. There are 198 malignant tumors in rare tumors. The number of rare tumor cases is not very high, but all rare tumors together account for about 20% of malignant tumor patients.
Yu Shiying revealed that rare tumors occur mainly in rare populations, rare sites, as well as rare pathological types. For example, children and adolescents are among the rare populations with cancer. Once a patient found Professor Yu Shiying, the child's stomach grew a large block, parents have not paid attention to, think is the child fat did not care, wait until serious to go to the hospital to find that is a long tumor, fortunately timely surgical removal and chemotherapy to avoid the tragedy, and such incidents in Professor Shiying's outpatient clinic sometimes occur. "All tumors in children are rare. At present, the more common tumors are leukemia, lymphoma and so on, as well as solid tumors, such as nephritary cell tumors, neuroblastoma, reproductive cell tumors and so on.
at present, compared with common tumors, there are many shortcomings in the diagnosis, treatment, medical insurance payment, basic research and new drug development. We should divide some of the forces to support the diagnosis and treatment of rare tumors. Rare tumors are not curable, such as children's cancer root rate has reached 80%, do not give up easily. Rare tumor clinics are scattered, professionals lack of training in rare tumor diagnosis and treatment, rare tumor super-adaptive drug use and limited medical insurance payment, etc. , are urgent to solve.
Yu Shiying suggested that rare tumors should be included in the list of rare diseases, rare tumors should be given equal attention. From a policy perspective to support the sub-specialty of rare tumors, and related scientific research, to solve the problem of hyper-adaptive drug use, optimize the problem of patient medication. From a medical point of view, we need our medical staff, there is sufficient training in rare tumor medicine to avoid missed and misdiagnosed. From a patient's perspective, the public also needs to pay more attention to rare tumors.
proton therapy is currently the most advanced radiation therapy technology
"about 70% of tumor patients need to receive radiation therapy, and proton therapy is the most advanced radiation therapy technology", Wuhan Concord Hospital Institute of Oncology Radiation Therapy Director Wu Gang in an interview with the Health Times, said that the current proton therapy in the accuracy and application of new technology is no less than traditional photonic therapy, in a significant reduction in the treatment of toxic side effects at the same time, the efficacy has also improved.
According to data provided by Professor Jiang Guoliang, Vice President of the China Anti-Cancer Association, Director of the Technical Committee of Shanghai Proton Heavy Ion Hospital and former Director of Fudan University Affiliated Oncology Hospital, nearly 3,000 patients have been treated in the past five years at the Proton Heavy Ion Treatment Center of Fudan University Cancer Hospital. On the whole, the toxic side effects of treatment were significantly less than photonic radiotherapy, and the efficacy was improved.
so-called proton therapy, colloquially speaking, is the use of medical proton accelerators to accelerate the formation of protons with positive charge of beam rays, accurate bombardment of tumor tissue, so that tumor cells are exposed to very high doses of ionizing radiation damage and death of the latest radiation therapy technology.
Wugang, the traditional radiation therapy is mostly the use of X-rays, which in the flow of tumor tissue energy is slowly increased and slowly decreased, easy to cause greater damage to normal tissue around the tumor. The ray energy of proton therapy can suddenly rise or fall at a certain tissue depth, so that the peak energy of the ray can be controlled in the tumor area, thus achieving better protection of normal tissue."We have to find a balance between tumor treatment effectiveness and toxic side effects, which, with proton therapy, will increasingly tilt toward the therapeutic effect,"
. Wu said.
October 2018, the National Health and Care Commission issued the "2018-2020 National Large-scale Medical Equipment Configuration Plan" proposed that by the end of 2020, the national plan to add 1500 large-scale radiotherapy equipment.
Wugang said that the development of radiation therapy in various regions of China is still uneven, and the level of homogenization of physicians is not high. In the next stage, we should further expand the number of county hospitals with large-scale radiotherapy equipment configuration, strengthen the training of radiotherapy professionals, and apply a large number of artificial intelligence technology, make use of cloud platforms to make county hospitals and provincial hospitals form a consortium, and improve the treatment level of county hospitals.
.